贵州百灵被预处罚，股民索赔可期

Core Viewpoint - Guizhou Bailing Pharmaceutical Group Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for financial misconduct, including underreporting sales expenses and overstating profits in multiple fiscal years [2][3]. Financial Misconduct Summary - Guizhou Bailing failed to adhere to the accounting standards, resulting in the following discrepancies: - In 2019, sales expenses were understated by 350.12 million yuan, leading to an overstatement of profits by the same amount, which constituted 95.73% of the reported profit for that year [2]. - In 2020, the company understated sales expenses by 240.81 million yuan, resulting in a profit overstatement of 240.81 million yuan, which was 115.35% of the reported profit [2]. - In 2021, sales expenses were understated by 63.79 million yuan, leading to a profit overstatement of 63.79 million yuan, accounting for 45.04% of the reported profit [2]. - In 2023, sales expenses were overstated by 459.41 million yuan, resulting in an understatement of profits by the same amount, which was 93.17% of the reported profit [2]. Legal and Regulatory Actions - The CSRC plans to impose penalties on Guizhou Bailing, its actual controller Jiang Wei, and other responsible personnel, including warnings and fines [2]. - Investors affected by the company's financial misstatements may seek civil compensation for losses incurred due to the misleading information [3]. - A lawyer from Shanghai Hanlian Law Firm is actively recruiting investors who purchased Guizhou Bailing's securities before April 30, 2024, to assist in filing compensation claims [3][4]. Investor Compensation Process - Investors can register for compensation if they bought Guizhou Bailing's stocks or bonds before April 30, 2024, and sold or held them afterward [3]. - Required materials for compensation registration include a copy of the ID, original securities account confirmation, and original transaction records [4].